60 results
424B5
IMPLQ
Impel Pharmaceuticals Inc
5 Oct 23
Prospectus supplement for primary offering
5:19pm
to the COVID-19 pandemic, the majority of our employees continue to work remotely as of September 30, 2023. As a result, we may have increased … stockholders;
require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;
authorize
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
4 Oct 23
Entry into a Material Definitive Agreement
5:21pm
(Minimum Net Revenue and Product Units Sold) for the three-week period ended on October 6, 2023 and has requested that the Majority Lenders waive … compliance with Section 10.02 for the three week period ended on October 6, 2023 (the “Additional Waiver”);
WHEREAS, upon an Event of Default the Majority
8-K
EX-10.4
IMPLQ
Impel Pharmaceuticals Inc
7 Sep 23
Entry into a Material Definitive Agreement
4:19pm
of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board … whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose
8-K
EX-10.1
g191fdrof3tp9lqm86
7 Sep 23
Entry into a Material Definitive Agreement
4:19pm
8-K
EX-10.1
ujk7kkcpxvqmp
21 Aug 23
Entry into a Material Definitive Agreement
8:33am
PRE 14A
wxq854
14 Apr 23
Preliminary proxy
4:11pm
10-K/A
EX-3.2
fq0z ekdd
31 Mar 23
Annual report (amended)
4:21pm
424B5
kow4aua
24 May 22
Prospectus supplement for primary offering
4:32pm
S-3
EX-4.4
f8cch
16 May 22
Shelf registration
4:49pm
S-3
EX-4.3
ilumc6rb
16 May 22
Shelf registration
4:49pm
S-3
7xqh71
16 May 22
Shelf registration
4:49pm